Login to Your Account



Immatics' IMA910 Unveils Solid Phase II Data in CRC at ASCO

By Nuala Moran
Staff Writer

Wednesday, June 6, 2012
LONDON – Cancer vaccines specialist immatics Biotechnologies GmbH released new Phase II data showing advanced colorectal cancer patients who mount an immune response to its IMA910 vaccine have significantly longer overall survival than those receiving standard of care.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription